Abstract. Toll-like receptors (TLRs) serve a vital role in activating the innate immune system by sensing conserved microbial products. Fc γ receptor IIb (FcγRIIb), the inhibitory Fc receptor, exerts its immune regulatory functions by binding to the immunoglobulin G Fc domain. Although the individual roles of TLRs and FcγRIIb have been studied intensively, the cross-talk between FcγRIIb and TLR4 on B cells remains unknown. The present study demonstrated that FcγRIIb ligation by the immune complex (IC) attenuated the TLR4-triggered nuclear factor (NF)-κΒ activation, and decreased the release of interleukin (IL)-6 from B cells, via enhancing LYN proto-oncogene (Lyn) phosphorylation. In addition, IC treatment protected mice from lethal endotoxic shock. Accordingly, IC decreased the LPS-induced serum levels of IL-6, as well as intracellular IL-6 production in B cells in vivo. However, these protective and inhibitory effects of IC were not observed in FcγRIIb -/-mice. In conclusion, the present data demonstrated that FcγRIIb inhibited TLR4 signaling in B cells by activating Lyn phosphorylation and by inhibiting NF-κΒ signaling. The present study elucidated the mechanism associated with the TLR4 and FcγRIIb cross-talk in B cells.
Introduction
Upon recognition of microbial conserved structures, such as lipopolysaccharide (LPS) and viral RNA, toll-like receptors (TLRs) are triggered to induce pro-inflammatory cytokines production, thus serving important roles in the initiation of innate immunity (1) . The TLR intracellular signaling pathway has been studied intensively. Binding of TLR4 agonist, LPS, to TLR4 activates myeloid differentiation protein 88 (MyD88)-dependent signaling, leading to the activation of mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-κΒ pathways, and contributing to the release of pro-inflammatory cytokines (2, 3) . Increased production of pro-inflammatory cytokines causes damage to the host and induces pathological inflammation. Dampening TLR signaling has therefore attracted much attention as a potential therapeutic for immune-related diseases (1, 2) . There are numerous reports of TLR4 signaling pathway relying on a series of phosphorylation events. For example, LPS stimulation results in myeloid differentiation factor-2 (MD-2) phosphorylation which is required for NF-κB activation (4) . MD-2 phosphorylation is dependent on the Src kinase, LYN proto-oncogene (Lyn) (4) . In addition, another report has suggested that Lyn positively controls TLR4-induced NF-κB activation, via regulating the activity of tumor necrosis factor (TNF) receptor-associated factor 6/tumor growth factor-β-activated kinase complex (5) . Thus, regulation of phosphorylation events via kinases may be used as a potential target to dampen TLR4 signaling.
The Fc portion of immunoglobulin (Ig) G is recognized by Fc γ receptors (FcγRs). FcγRs exist in two functional subtypes: Immunoreceptor tyrosine-based activation motif (ITAM)-containing FcγRs (such as FcγRI and FcγRIIa) and immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing FcγRs (FcγRIIb). The inhibitory FcγRIIb counters the actions of activating FcγRs (6, 7) . As an example, co-ligation of FcγRIIa by aggregated IgG induces activation of ITAM, whereas cross-linking of FcγRIIb by immune complex (IC) initiates activation of ITIM and subsequent recruitment of SH2-domain-containing inositol phosphatase 1 (SHIP-1), ultimately resulting in the inhibition of ITAM activation pathways (8, 9) . Most immunocytes, such as macrophages and dendritic cells (DCs), co-express activating and inhibitory FcγRs, but B cells are reported to only express the inhibitory receptor FcγRIIb, which functions to downregulate B-cell receptor-mediated activation pathways by IC (6, 7) .
The 
Materials and methods

Mice.
A total of 135 male C57BL/6J mice (5-6 weeks of age, 17-21 g) were purchased from the Animal Center of Yangzhou University (Yangzhou, China). A total of 45 male FcγIIb -/-mice on a C57BL/6J background (5-6 weeks of age, 17-21 g) were purchased from Jackson Laboratory (Ben Harbor, ME, USA). All mice were maintained in an animal facility at 22-24˚C with 50-60% humidity, a 12-h light/dark cycle and with free access to food and water. Animal experiments were conducted with approval from the Institutional Animal Care and Use Committee of Yangzhou University.
IC preparation. IC was generated as described previously (11) . Briefly, anti-ovalbumin (OVA) antibody (Ab; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) was incubated with OVA (Sigma-Aldrich; Merck KGaA) at a 10:1 mass ratio at 37˚C for 1 h. For in vitro experiments, IC was used at a concentration of 10 µg/ml OVA + 100 µg/ml anti-OVA. IC injection and endotoxic shock. IC was injected intraperitoneally into mice for 24 h and then 20 mg/kg of LPS was injected intraperitoneally into the IC-pretreated mice. Survival rate was monitored for 4 days. In some experiments, the mice were sacrificed 2 h following LPS injection. Blood samples were acquired for IL-6 detection in sera. Splenic single-cell suspensions were prepared as reported (17) for intracellular IL-6 detection in B cells.
IL-6 measurement.
For detecting IL-6 in sera and culture supernatants, a CBA Flex Set kit (BD Biosciences, San Jose, CA, USA) was used following the manufacturer's protocol. For measurement of intracellular IL-6 in B cells, single cell suspensions were incubated with brefeldin A (Sigma-Aldrich; Merck KGaA) at 10 µg/ml for 6 h, and labeled with anti-CD19 (cat. no. 553785; BD Biosciences) and anti-IL-6 (cat. no. 554401; BD Biosciences) or isotype-matched Ig control Abs (cat. no. 554685; BD Biosciences) at 1:20 dilution using a Cytofix/Cytoperm kit (BD Biosciences) following the manufacturer's protocol. Results from both assays were analyzed by flow cytometry. Flow cytometry was done with a FACSCalibur (BD Biosciences) and data were analyzed with FlowJo version 10.0 software (FlowJo, LLC, Ashland, OR, USA).
Statistical analysis. For comparisons between two groups, data were analyzed using Student's t-test. For comparisons among multiple groups, data were analyzed using one-way analysis of variance followed by the Tukey post hoc test. GraphPad Prism version 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA) was used for data analysis. Survival curves were drawn using GraphPad Prism 5.0 (GraphPad Software, Inc.), and survival analysis was performed using the log-rank (Mantel-Cox) test.
Results
IC inhibits LPS-triggered IL-6 release from B cells via
FcγRIIb. B cells were stimulated with IC and LPS for 24 h and then cytokine production was examined in the supernatants. IC treatment did not affect TNF-α, IL-1β, interferon (IFN) γ and IFNγ-induced protein 10 production (data not shown). However, IL-6 secretion was significantly inhibited in B cells stimulated with 200-800 ng/ml LPS, compared with unstimulated B cells (Fig. 1A) . As illustrated in Fig. 1B , IC treatment inhibited IL-6 production in LPS-activated B cells in a dose-dependent manner. Furthermore, LPS-activated B cells exhibited attenuated IL-6 secretion when pretreated with IC for 24 h (Fig. 1C) . However, IC treatment could not inhibit LPS-induced IL-6 secretion in B cells, if LPS stimulation had already occurred prior to IC treatment (Fig. 1D) . Considering that IC is formed from free OVA and anti-OVA Ab, the effect of free OVA or anti-OVA Ab treatment alone on LPS-induced IL-6 production was tested as a control. As illustrated in Fig. 1E , free OVA did not reduce LPS-triggered IL-6 secretion, while the ability of the anti-OVA Ab alone to inhibit IL-6 production was significantly decreased compared with IC treatment. To further confirm that FcγRIIb mediated the inhibitory action of IC on IL-6 release in LPS-activated B cells, B cells from FcγRIIb -/-mice were activated with IC and LPS. As demonstrated in Fig. 1F , the inhibitory action of IC on LPS-triggered IL-6 secretion was lost in FcγRIIb -/-B cells. These results indicated that FcγRIIb mediated the inhibitory effect of IC on B cell IL-6 production.
IC inhibits LPS-triggered NF-κB activation via FcγRIIb.
It is reported that TLR4 ligation activates the MAPK and NF-κB pathways, resulting in the production of pro-inflammatory cytokines (18) . As illustrated in Fig. 2A , LPS-induced NF-κB activation (demonstrated by the phosphorylation of IKKα/β, IκBα and p65) was inhibited in IC-treated B cells, compared with B cells treated with LPS alone. By contrast, phosphorylation of ERK, JNK and p38 was not affected by IC treatment (Fig. 2B) , indicating that the MAPK pathway is not involved in the IC-mediated inhibition of IL-6 production in B cells. Pretreatment with the NF-κB inhibitor PDTC significantly blocked IL-6 production in LPS-stimulated B cells (Fig. 2C) , suggesting that NF-κB activation is necessary for B cells to produce high levels of IL-6. Furthermore, LPS activated-B cells deficient in FcγRIIb displayed similar levels of p-IκBα and p-p65 with or without IC treatment (Fig. 2D) , suggesting that FcγRIIb mediates the inhibitory action of IC on LPS-triggered NF-κB activation.
Lyn downregulates LPS-triggered IL-6 secretion by inhibiting NF-κB pathway activation.
In order to explore which signal molecule may mediate the function of IC in inhibiting TLR4-mediated NF-κB activation, the activation status of various tyrosine kinases (Lyn, Btk and Syk) was examined in IC-stimulated B cells. Btk and Syk exhibited a similar activation status in B cells with or without IC stimulation, while phosphorylation of Lyn, one of the Src family members, was markedly increased in wild-type B cells following IC stimulation (Fig. 3A) . However, phosphorylation of Lyn was not altered (Fig. 3B) , suggesting that IC-induced Lyn activation is FcγRIIb dependent. To explore the role of Lyn in the LPS-induced activation of the NF-κB pathway, B cells were pretreated with radicicol, an inhibitor of p-Lyn, and then stimulated with LPS. As illustrated in Fig. 3C , radicicol enhanced the LPS-induced NF-κB activation, as measured by phosphorylation of IκBα and p65. In addition, the inhibitory effect of IC on IL-6 production in LPS-activated B cells was abrogated following radicicol treatment (Fig. 3D) . These results demonstrated that IC inhibits LPS-triggered IL-6 production in B cells by enhancing Lyn activation and subsequently suppressing the NF-κB pathway. Fig. 1 , IC suppressed IL-6 secretion in LPS-activated B cells in vitro. Therefore, the hypothesis that IC may exhibit a protective effect on LPSinduced endotoxic shock was tested in vivo. As illustrated in Fig. 4A , WT mice died within 2 days following LPS intraperitoneal administration. However, only ~30% of IC-pretreated WT mice died within 3 days, suggesting that pretreatment of IC protected the mice from endotoxic shock (Fig. 4A) . When FcγIIb -/-mice were tested, IC pretreatment did not protect the mice from endotoxic shock and the mice died within 3 days following administration of LPS (Fig. 4A) . Similar to results obtained with B cells in vitro, IC-pretreatment resulted in decreased IL-6 expression levels in the sera (Fig. 4B ) and the splenic B cells (Fig. 4C) of the LPS-treated mice, compared with mice treated with LPS alone. By contrast, IL-6 expression levels in the sera and the splenic B cells of LPS-treated FcγIIb -/-mice remained unchanged by IC pretreatment (Fig. 4B and C) . Taken together, these results suggested that IC exhibited a protective effect on LPS-induced endotoxic shock via FcγIIb in vivo.
IC protects mice from endotoxic shock in an FcγRIIb-dependent manner. As demonstrated in
Discussion
TLRs serve a crucial role in allowing immune cells, such as DCs and macrophages, to recognize microbial pathogens and initiate protective responses. However, TLRs have also been reported to take part in the development of several inflammatory and autoimmune diseases (1) . FcγRIIb has been reported to be important in regulating Abs generation. A recent study has highlighted new functions for FcγRIIb, such as inhibiting the innate immune system via downregulating TLR signaling (19) .
Antigen-presenting cells, including DCs, B cells and macrophages, co-express TLRs and FcγRIIb (7, 13) . Previous studies indicate that DCs from patients with rheumatoid arthritis express high levels of FcγRIIb and that these FcγRIIb-expressing DCs inhibit TLR4-triggered production of TNF-α and IL-12p70 following IC stimulation (10) . Blocking FcγRIIb with specific Abs fully abrogated the inhibitory role of IC on TLR4-triggered TNF-α production, suggesting that FcγRIIb mediates the inhibitory role of IC on TLR4 signaling in DCs (10) . IC/Ig has also been reported to negatively regulate TLR4-triggered IL-6 and TNF-α production through FcγRIIb in macrophages (11) . In the present study, IC/Ig was demonstrated to suppress TLR4-triggered IL-6 secretion, but not TNF-α production, in B cells. A previous study has reported that LPS-triggered IL-6 release from RAW264.7 macrophages is inhibited by 16α, 17α-epoxypregnenolone-20-oxime (EPREGO), but EPREGO does not affect TNF-α secretion (20) . Therefore, it is possible that LPS may induce activation of different signaling pathways for different cytokine secretion and the signaling pathways responsible for IL-6 secretion, but for TNF-α secretion, are inhibited by IC. In macrophages, prostaglandin E2 (PGE2) has been reported to be responsible for the inhibitory effect of IC on TLR4 signaling (11) . When testing whether PGE2 is involved in IC function in B cells, results demonstrated that IC induced PGE2 production in an FcγRIIB-independent manner and PGE2 was not responsible for the IC-mediated inhibitory effect in B cells (data not shown). Thus, different mechanisms may account for the inhibitory effect of IC on TLR4 pathway in different cell types.
The mechanisms underlying the FcγRIIb-mediated inhibition of TLR4 have not yet been fully identified (10) . It has been reported that CD11b inhibits TLR4 pathway activation by activating Src and Syk tyrosine kinases (21) . In the present study, various tyrosine kinases were screened and Lyn, a member of the Src family of cytoplasmic tyrosine kinases, was demonstrated to be involved. Inhibiting Lyn resulted in an increase of TLR4-mediated NF-κB activation and IL-6 production from B cells in vitro. Lyn has been reported to phosphorylate adaptor molecules, such as Dok proteins, which sustain SHIP-1 activation and inhibit NF-κB pathway activation (22, 23) . Thus, Dok proteins may be involved in the cross-talk between FcγRIIb and TLR4. It has also been reported that the tyrosine kinase Syk induces MyD88 and TIR-domain-containing adapter inducing interferon-β (TRIF) activation, resulting in their degradation by the E3 ubiquitin ligase Cbl-b, and subsequent inhibition of TLR signaling in innate immune responses (21) . These findings raise the possibility that FcγRIIb may inhibit TLR4-mediated signaling via Lyn activation and MyD88 and TRIF degradation. Further studies are required to fully elucidate the exact mechanism by which Lyn activation inhibits the TLR4-triggered NF-κB pathway. To date, inhibition of TLR4-induced pro-inflammatory cytokine production by IC has been reported in vitro for various immunocytes, such as DCs and macrophages (10, 11) . The present study demonstrated that B cells pretreated with IC exhibited decreased IL-6 production following LPS activation both in vitro and in vivo, and IC protected mice from LPS-induced endotoxic shock via FcγIIb. Because overproduction of pro-inflammatory cytokines induces acute endotoxic shock and chronic pathological inflammation (24) , the present study, together with others, may provide novel therapeutic approaches for treating TLR4-mediated pathological inflammation. Furthermore, IC pretreatment decreased TNF-α expression levels in the sera, of mice but not in the splenic B cells (data not shown), suggesting that B cells are not responsible for the decreased TNF-α levels in sera. Death caused by LPS challenge in mice is more likely due to the high levels of TNF-α. Macrophages and other myeloid cells are the major source of inflammatory cytokines during sepsis. Thus, macrophages or other myeloid cells may serve more important roles than B cells in the therapeutic effect of IC.
Taken together, the present results demonstrated that IC negatively regulated TLR4 signaling in B cells via FcγIIb and Lyn activation. These findings may add insights to the mechanism by which FcγIIb and TLR4 cross-talk to prohibit damage to host tissues from exaggerated immune responses, such as in sepsis.
